t cell costimulatory and coinhibitory pathways in vascular inflammatory diseases
Clicks: 374
ID: 227737
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
77.5
/100
374 views
276 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #22 of 461 articles by views in Journal of clinical and experimental dentistry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 461 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
A broad array of evidence indicates that T lymphocytes make significant contributions to vascular inflammation in the setting of atherosclerotic disease, hypertension, autoimmune vasculitis, and other disorders. Experimental data show that costimulatory and coinhibitory pathways involving molecules of the B7-CD28 and TNF-TNFR families regulate T cell responses that promote vascular disease. Antigen presenting cells display both peptide-MHC antigen and costimulators or coinhibitors to T cells. Two major types of antigen presenting cells, dendritic cells and macrophages, are present in significant numbers in the walls of arteries affected by atherosclerosis and arteritis, and some dendritic cells are present in normal arteries. Costimulatory and coinhibitory molecules expressed by these vascular antigen presenting cells can contribute to the activation or inhibition of effector T cells within the arterial wall. Vascular dendritic cells may also be involved in transport of antigens to secondary lymphoid organs, where they activate or tolerize naïve T cells, depending on the balance of costimulators and coinhibitors they express. Costimulatory blockade is already an approved therapeutic approach to treat autoimmune disease and prevent transplant rejection. Preclinical models suggest that costimulatory blockade may also be effective in treating vascular disease. Experiential data in mice show that dendritic cells pulsed with the appropriate antigens and treated in a way that reduces costimulatory capacity can reduce atherosclerotic disease, presumably by inducing T cell tolerance. Progress in treating vascular disease by immune modulation will require a more complete understanding of the functions of different costimulatory and coinhibitory pathways and the different subsets of vascular antigen presenting cells involved.
| Reference Key |
elichtman2012frontierst
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Andrew eLichtman |
| Journal | Journal of clinical and experimental dentistry |
| Year | 2012 |
| DOI |
10.3389/fphys.2012.00018
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.